DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Velusetrag
Velusetrag
New Developments in Prokinetic Therapy for Gastric Motility Disorders
Serotonin Receptors and Their Role in the Pathophysiology and Therapy of Irritable Bowel Syndrome
Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
Gastroparesis - Recent Advances in the Pathophysiology and Treatment
New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety
Gastroparesis: 2014
G Protein-Coupled Receptors
G Protein‐Coupled Receptors
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
ZELNORM™ (Tegaserod Maleate) for the Treatment of Irritable Bowel
For Idiopathic and Diabetic Gastroparesis
Recent Advances in Understanding and Managing Chronic Constipation [Version 1; Peer Review: 2 Approved] David O
Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects Of
Prokinetics in the Management of Functional Gastrointestinal Disorders
The Effects of 5-Ht4 Receptor Agonists on Interleukin-10 Knockout Mice" (2018)
Lubiprostone: Evaluation of the Newest Medication for the Treatment of Adult Women with Constipation-Predominant Irritable Bowel Syndrome
5-HT Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders
Top View
Metoclopramide: a Template for Drug Discovery
RMM Art 2.Indd
Brain-Gut Interactions in IBS
Efficacy of Combination Therapy with Probiotics and Mosapride In
Therapeutic Modulators of the Serotonin 5
How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome
(TD-5108) for Treatment of Gastroparesis in "Poster of Distinction" at Digestive Disease Week (DDW) 2015
Pharmacotherapy for Irritable Bowel Syndrome
(12) Patent Application Publication (10) Pub. No.: US 2016/0082123 A1 RAU Et Al
5108 Ph 2B 099 Presentation
Irritable Bowel Syndrome and Constipation Agents
THE Herg1 (KV11.1) POTASSIUM CHANNEL: ITS MODULATION and the FUNCTIONAL CHARACTERISATION of GENETIC VARIANTS
(12) Patent Application Publication (10) Pub. No.: US 2014/0243254 A1 Hersel Et Al
Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management
Prokinetics in Chronic Constipation
Theravance and Alfa Wassermann Announce Initiation of Phase 2 Study with Velusetrag for Gastroparesis
Adam M. Van Dyke
[email protected]
Clinical Guideline: Management of Gastroparesis
G Protein-Coupled Receptors
Drugs Affecting 5-HT Systems
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
The Concise Guide to PHARMACOLOGY 2015/16
Velusetrag and TD-8954, Selective 5-HT4 Receptor Agonists
Disorders of Gastrointestinal Hypomotility[Version 1; Peer Review
New Therapeutic Perspectives in Irritable Bowel Syndrome: Targeting Low-Grade Inflammation, Immuno-Neuroendocrine Axis, Motility, Secretion and Beyond
FDA Briefing Document Gastrointestinal Drug Advisory Committee Meeting